Liu Jiali, Huang Jinke, Zhang Beihua, Yin Xiaolan, Lv Mi, Liu Zhihong, Wang Fengyun, Tang Xudong
Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Institute of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Evid Based Complement Alternat Med. 2022 Jun 15;2022:1500660. doi: 10.1155/2022/1500660. eCollection 2022.
Systematic reviews/meta-analyses (SRs/MAs) are still controversial on the effectiveness of Banxia Xiexin decoction (BXD) to treat gastroesophageal reflux disease (GERD). To assess the evidence reliability and inform the clinical use of BXD, we performed a meta-analysis from previous SRs/MAs to collate, critically appraise, and synthesize the effectiveness of BXD treatment in GERD.
SRs/MAs were collected by searching major medical databases. The included studies were evaluated in terms of methodological quality and quality of evidence using criteria from the Assessment of Multiple Systematic Reviews 2 (AMSTAR-2) tool, and the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system, respectively.
Six SRs/MAs were included in this study. The methodological quality of SRs/MAs was generally unsatisfactory. Unregistered protocols, failure to provide a list of excluded trials, and lack of a comprehensive search strategy were the main limitations of previous SRs/MAs. No high-quality evidence was found to support the effect of BXD on GERD patients. The qualitative data synthesis relied on low-quality trials with a small sample size, which was the main factor for evidence degradation.
BXD seems to have promising efficacy to treat GERD patients. Although the quality of SRs/MAs was generally low and defects were frequent, our study highlights areas where methodologies need to be improved.
关于半夏泻心汤(BXD)治疗胃食管反流病(GERD)的有效性,系统评价/荟萃分析(SRs/MAs)仍存在争议。为评估证据的可靠性并指导BXD的临床应用,我们对既往的SRs/MAs进行了荟萃分析,以整理、严格评价并综合BXD治疗GERD的有效性。
通过检索主要医学数据库收集SRs/MAs。分别使用多重系统评价评估2(AMSTAR-2)工具的标准和推荐分级、评估、制定与评价(GRADE)系统,对纳入研究的方法学质量和证据质量进行评估。
本研究纳入了6项SRs/MAs。SRs/MAs的方法学质量总体上不尽人意。方案未注册、未提供排除试验列表以及缺乏全面的检索策略是既往SRs/MAs的主要局限性。未发现高质量证据支持BXD对GERD患者的疗效。定性数据综合依赖于样本量小的低质量试验,这是证据降级的主要因素。
BXD似乎对治疗GERD患者有良好疗效。尽管SRs/MAs的质量总体较低且缺陷频繁,但我们的研究突出了方法学需要改进的领域。